Search results for "Eryt"

showing 10 items of 966 documents

Short-term cactus pear [

2018

Background: Dietary ingredients and food components are major modifiable factors protecting immune system and preventing the progression of a low-grade chronic inflammation responsible for age-related diseases. Objective: Our study explored whether cactus pear (Opuntia ficus-indica, Surfarina cultivar) fruit supplementation modulates plasma inflammatory biomarkers in healthy adults. Correlations between inflammatory parameters and antioxidant status were also assessed in parallel. Design: In a randomised, 2-period (2 weeks/period), crossover, controlled-feeding study, conducted in 28 healthy volunteers [mean age 39.96 (±9.15) years, BMI 23.1 (±1.5) kg/m2], the effects of a diet supplemented…

0301 basic medicineantioxidant networkmedicine.medical_specialtyNecrosisAntioxidantmedicine.medical_treatmentInflammationlcsh:TX341-641030204 cardiovascular system & hematologyBiology03 medical and health sciences0302 clinical medicineInternal medicineNutrition and DieteticmedicineCarotenoidinflammatory biomarkerschemistry.chemical_classificationPEAR030109 nutrition & dieteticsNutrition and Dieteticsmedicine.diagnostic_testPublic Health Environmental and Occupational HealthInterleukinskin carotenoidscactus pear fruitSkin carotenoidEndocrinologychemistryErythrocyte sedimentation ratehealthy subjectsBiomarker (medicine)Original Articlemedicine.symptomHealthy subjectlcsh:Nutrition. Foods and food supplyInflammatory biomarkerFood ScienceFoodnutrition research
researchProduct

The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70.

2017

International audience; Diamond-Blackfan anemia (DBA) is a rare congenital bone marrow failure syndrome that exhibits an erythroid-specific phenotype. In at least 70% of cases, DBA is related to a haploinsufficient germ line mutation in a ribosomal protein (RP) gene. Additional cases have been associated with mutations in GATA1. We have previously established that the RPL11+/Mut phenotype is more severe than RPS19+/Mut phenotype because of delayed erythroid differentiation and increased apoptosis of RPL11+/Mut erythroid progenitors. The HSP70 protein is known to protect GATA1, the major erythroid transcription factor, from caspase-3 mediated cleavage during normal erythroid differentiation.…

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesIdentificationApoptosis-Inducing FactorGata1 MutationsInhibits ApoptosisBiologyHsp7003 medical and health sciencesGermline mutationRed Cells Iron and Erythropoiesishemic and lymphatic diseasesmedicine[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyNuclear ImportErythropoiesisDiamond–Blackfan anemiaHuman ErythroblastsBone marrow failure[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyGATA1Hematologymedicine.diseasePhenotypeMolecular biology3. Good healthHsp70030104 developmental biologyRibosomal-ProteinsProtein Gene DeletionsErythropoiesisHaploinsufficiencyBlood advances
researchProduct

Clinical Guide and Update on Porphyrias.

2019

Physicians should be aware of porphyrias, which could be responsible for unexplained gastrointestinal, neurologic, or skin disorders. Despite their relative rarity and complexity, most porphyrias can be easily defined and diagnosed. They are caused by well-characterized enzyme defects in the complex heme biosynthetic pathway and are divided into categories of acute vs non-acute or hepatic vs erythropoietic porphyrias. Acute hepatic porphyrias (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and aminolevulinic acid dehydratase deficient porphyria) manifest in attacks and are characterized by overproduction of porphyrin precursors, producing often serious abdomin…

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPorphyrinsGastrointestinal DiseasesVariegate porphyriaPorphobilinogenCongenital erythropoietic porphyriaGastroenterologySkin Diseases03 medical and health sciencesPorphyrias0302 clinical medicineInternal medicinemedicineHumansPorphyria cutanea tardaskin and connective tissue diseasesAcute intermittent porphyriaHepatologybusiness.industryHepatoerythropoietic porphyriaGastroenterologynutritional and metabolic diseasesAminolevulinic Acidmedicine.disease030104 developmental biologyHereditary coproporphyriaPorphyriaPractice Guidelines as Topic030211 gastroenterology & hepatologyErythropoietic protoporphyriaNervous System DiseasesbusinessGastroenterology
researchProduct

Macrophage protease-activated receptor 2 regulates fetal liver erythropoiesis in mice.

2020

AbstractDeficiencies in many coagulation factors and protease-activated receptors (PARs) affect embryonic development. We describe a defect in definitive erythropoiesis in PAR2-deficient mice. Embryonic PAR2 deficiency increases embryonic death associated with variably severe anemia in comparison with PAR2-expressing embryos. PAR2-deficient fetal livers display reduced macrophage densities, erythroblastic island areas, and messenger RNA expression levels of markers for erythropoiesis and macrophages. Coagulation factor synthesis in the liver coincides with expanding fetal liver hematopoiesis during midgestation, and embryonic factor VII (FVII) deficiency impairs liver macrophage development…

0301 basic medicinemedicine.medical_specialtyBiologyThrombosis and Hemostasis03 medical and health sciencesMice0302 clinical medicineHepcidinInternal medicinemedicineMacrophageAnimalsReceptor PAR-2ErythropoiesisProtease-activated receptor 2Mice KnockoutFetusMacrophagesHematologymedicine.diseaseHemolysisHaematopoiesis030104 developmental biologyEndocrinologymedicine.anatomical_structureLiver030220 oncology & carcinogenesisbiology.proteinErythropoiesisBone marrowBlood advances
researchProduct

Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders

2021

Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classification 1970) divided the primary hyperviscosity syndromes in polycythaemic, sclerocytemic and sieric. Recent and personal laboratory observations have highlighted an unexpected behaviour of the erythrocyte deformability observed in some haematological disorders such as polycythemia vera, multiple myeloma and monoclonal gammopathy of undetermined significance. The interest of this observation depends on the fact that up to now, according to the Wells cla…

0301 basic medicinemedicine.medical_specialtyLaboratory findingHyperviscosityMonoclonal gammopathy of undetermined significance030204 cardiovascular system & hematologyBiochemistryHyperviscosity syndromes03 medical and health sciences0302 clinical medicinePolycythemia veraMultiple myelomaErythrocyte DeformabilityHyperviscosity syndromemedicineAnimalsHumansIntensive care medicinePolycythemia VeraMultiple myelomabusiness.industryModels CardiovascularCell Biologymedicine.diseaseBlood Viscosity030104 developmental biologyAbnormalityCardiology and Cardiovascular MedicinebusinessMonoclonal gammopathy of undetermined significanceHaematological disorders
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way?

2016

Traumatic brain injury (TBI) is a leading cause of death and disability in the modern society. Although primary prevention is the only strategy that can counteract the primary brain damage, numerous preclinical studies have been accumulated in order to find therapeutic strategies against the secondary damage. In this scenario erythropoietin (EPO) has been shown to be a promising candidate as neuroprotective agent. A recent clinical trial, however, has shown that EPO has not an overall effect on outcomes following TBI thus renewing old concerns.  However, the results of a prespecified sensitivity analysis indicate that the effect of EPO on mortality remains still unclear. In the light of the…

0301 basic medicinemedicine.medical_specialtyMolecular PharmacologyNeuropharmacology & PsychopharmacologyTraumatic brain injurySolid baseBrain damageNeuroprotectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTraumatic brain injury0302 clinical medicinePrimary preventionmedicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineErythropoietin; Neuroprotection; Traumatic brain injuryErythropoietinCause of deathGeneral Immunology and Microbiologybusiness.industryArticlesGeneral MedicineOpinion Articlemedicine.diseaseNeuroprotectionClinical trial030104 developmental biologyErythropoietinmedicine.symptombusinessNeuroscience030217 neurology & neurosurgerymedicine.drugF1000Research
researchProduct

X-linked protoporphyria: Iron supplementation improves protoporphyrin overload, liver damage and anaemia

2015

0301 basic medicinemedicine.medical_specialtybusiness.industryHematologymedicine.disease03 medical and health sciencesLiver diseasechemistry.chemical_compound030104 developmental biologyEndocrinologyPorphyriachemistryInternal medicineHaem biosynthesisIron supplementationMedicineErythropoiesisProtoporphyrinLiver damagebusinessBritish Journal of Haematology
researchProduct

High HFE mutation incidence in idiopathic erythrocytosis.

2018

0301 basic medicinemedicine.medical_specialtybusiness.industryIncidence (epidemiology)IncidenceHematologyPolycythemiaGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicineMutation (genetic algorithm)MutationmedicineHumansIdiopathic erythrocytosisbusinessHemochromatosis ProteinBritish journal of haematology
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct